NCT00452504View on ClinicalTrials.gov

Single Ascending Dose Study of SRA-444 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

February 28, 2007

Study Completion Date

June 30, 2007

Conditions

Alzheimer Disease

Interventions

DRUG

SRA-444

Trial Locations (1)

9470 AE

Zuidlaren

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00452504 - Single Ascending Dose Study of SRA-444 in Healthy Subjects | Biotech Hunter | Biotech Hunter